At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 243 enrolled
Drug / intervention
Semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Semaglutide, Placebo, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 243 participants across 16 sites.
Detailed Summary
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionJan 2018
Study CompletionAug 2018
TodayJul 2026
First PostedJan 11, 2017
Enrollment StartJan 10, 2017
Primary CompletionJan 9, 2018
Study CompletionAug 15, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 9.5 years ago
Interventions
Semaglutidedrug
Oral administration once daily
Placebodrug
Oral administration once daily
Liraglutidedrug
Subcutaneous (s.c., under the skin) injection once daily